Targeting HIV-1 integrase with strand transfer inhibitors

Drug Discovery Today

Volumn 20, Issue 4, 2015, Pages 435-449

  Li, Yang ^a   Xuan, Shouyi ^a   Feng, Yue ^a   Yan, Aixia ^a  

^a BEIJING UNIVERSITY OF CHEMICAL TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; INTEGRASE; INTEGRASE INHIBITOR; LIGAND; P31 INTEGRASE PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; PROTEIN BINDING;

ANIMAL; BINDING SITE; BIOLOGY; CHEMICAL STRUCTURE; CHEMISTRY; CLUSTER ANALYSIS; COMPUTER AIDED DESIGN; DRUG DESIGN; DRUG EFFECTS; ENZYME ACTIVE SITE; ENZYMOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; MOLECULARLY TARGETED THERAPY; PROTEIN CONFORMATION; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-HIV AGENTS; BINDING SITES; CATALYTIC DOMAIN; CLUSTER ANALYSIS; COMPUTATIONAL BIOLOGY; COMPUTER-AIDED DESIGN; DRUG DESIGN; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; PROTEIN BINDING; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84939953026     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.12.001     Document Type: Review

References (109)

1. http://www.unaids.org/en/dataanalysis/ (accessed July 2014)
2. R. Dayam HIV-1 integrase inhibitors: 2003-2004 update Med. Res. Rev. 26 2006 271 309
3. J. Demeulemeester Fueling HIV-1 integrase drug design with structural insights Drug Discov. Today Technol. 9 2012 e205 e212
4. http://www.aidsinfo.nih.gov/drugs (accessed November 2014)
5. J.P. Lalezari Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America N. Engl. J. Med. 348 2003 2175 2185
6. P. Dorr Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity Antimicrob. Agents Chemother. 49 2005 4721 4732
7. P. Bonfanti HIV disease treatment in era of HAART Biomed. Pharamacother. 53 1999 93 105
8. S. Gupta Brain injury caused by HIV protease inhibitors: role of lipodystrophy and insulin resistance Antivir. Res. 95 2012 19 29
9. E. Asante-Appiah HIV-1 integrase: structural organization, conformational changes, and catalysis Adv. Virus Res. 52 1999 351 369
10. Y. Pommier Retroviral integrase inhibitors year 2000: update and perspectives Antivir. Res. 47 2000 139 148
11. R. Zheng Zinc folds the N-terminal domain of HIV-1 integrase, promotes multimerization, and enhances catalytic activity Proc. Natl. Acad. Sci. U. S. A. 93 1996 13659 13664
12. M. Cai Solution structure of the N-terminal zinc binding domain of HIV-1 integrase Nat. Struct. Mol. Biol. 4 1997 567 577
13. P. Brown Retroviruses 1997 Cold Spring Harbor Lab. Press 161 203
14. J.C.-H. Chen Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding Proc. Natl. Acad. Sci. U. S. A. 97 2000 8233 8238
15. A.P. Eijkelenboom The DNA-binding domain of HIV-1 integrase has an SH3-like fold Nat. Struct. Mol. Biol. 2 1995 807 810
16. D. Esposito, and R. Craigie HIV integrase structure and function Adv. Virus Res. 52 1999 319 333
17. C. Benard Linker-modified quinoline derivatives targeting HIV-1 integrase: synthesis and biological activity Bioorg. Med. Chem. Lett. 14 2004 2473 2476
18. G. Chi Inhibition of the strand transfer step of HIV-1 integrase by non-natural dinucleotides Bioorg. Med. Chem. Lett. 14 2004 4815 4817
19. E.E. Boros Synthesis and HIV-integrase strand transfer inhibition activity of 7-hydroxy[1,3]thiazolo[5,4-b]pyridin-5(4H)-ones Bioorg. Med. Chem. Lett. 16 2006 5668 5672
20. Y. Goldgur Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design Proc. Natl. Acad. Sci. U. S. A. 96 1999 13040 13043
21. K.A. Jurado Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation Proc. Natl. Acad. Sci. U. S. A. 110 2013 8690 8695
22. F. Christ Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication Nat. Chem. Biol. 6 2010 442 448
23. M. Tsiang New class of HIV-1 integrase (IN) inhibitors with a dual mode of action J. Biol. Chem. 287 2012 21189 21203
24. T.S. Peat Small molecule inhibitors of the LEDGF site of human immunodeficiency virus integrase identified by fragment screening and structure based design PLoS ONE 7 2012 e40147
25. J.J. Kessl Multimode, cooperative mechanism of action of allosteric HIV-1 integrase inhibitors J. Biol. Chem. 287 2012 16801 16811
26. L. Feng The A128T resistance mutation reveals aberrant protein multimerization as the primary mechanism of action of allosteric HIV-1 integrase inhibitors J. Biol. Chem. 288 2013 15813 15820
27. http://www.rcsb.org/pdb/explore/explore.do?structureId=3WNE (accessed November 2014)
28. http://www.rcsb.org/pdb/explore/explore.do?structureId=3WNF (accessed November 2014)
29. http://www.rcsb.org/pdb/explore/explore.do?structureId=3WNG (accessed November 2014)
30. http://www.rcsb.org/pdb/explore/explore.do?structureId=3WNH (accessed November 2014)
31. J. Wielens Parallel screening of low molecular weight fragment libraries: do differences in methodology affect hit identification? J. Biomol. Screen. 18 2013 147 159
32. T.S. Peat Interrogating HIV integrase for compounds that bind - a SAMPL challenge J. Comput. Aided Mol. Des. 28 2014 347 362
33. J. Wielens Fragment-based design of ligands targeting a novel site on the integrase enzyme of human immunodeficiency virus 1 ChemMedChem 6 2011 258 261
34. D.I. Rhodes Structural basis for a new mechanism of inhibition of HIV-1 integrase identified by fragment screening and structure-based design Antivir. Chem. Chemother. 21 2011 155 168
35. J. Wielens Crystal structure of the HIV-1 integrase core domain in complex with sucrose reveals details of an allosteric inhibitory binding site FEBS Lett. 584 2010 1455 1462
36. M. Métifiot Activities, crystal structures, and molecular dynamics of dihydro-1 H-isoindole derivatives, inhibitors of HIV-1 integrase ACS Chem. Biol. 8 2012 209 217
37. B.A. Desimmie 2-Hydroxyisoquinoline-1,3(2H, 4H)-diones (HIDs), novel inhibitors of HIV integrase with a high barrier to resistance ACS Chem. Biol. 8 2013 1187 1194
38. R. Dayam, and N. Neamati Active site binding modes of the β-diketoacids: a multi-active site approach in HIV-1 integrase inhibitor design Bioorg. Med. Chem. 12 2004 6371 6381
39. S. Xuan Support vector machine (SVM) models for predicting inhibitors of the 3′ processing step of HIV-1 integrase Mol. Inf. 32 2013 811 826
40. A. Yan Classification of active and weakly active ST inhibitors of HIV-1 integrase using a support vector machine Comb. Chem. High Throughput Screen. 15 2012 792 805
41. S. Xuan Prediction of bioactivity of HIV-1 integrase ST inhibitors by multilinear regression analysis and support vector machine Bioorg. Med. Chem. Lett. 23 2013 1648 1655
42. R. Di Santo Novel bifunctional quinolonyl diketo acid derivatives as HIV-1 integrase inhibitors: design, synthesis, biological activities, and mechanism of action J. Med. Chem. 49 2006 1939 1945
43. P. Cherepanov HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells J. Biol. Chem. 278 2003 372 381
44. P. Cherepanov Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75 Proc. Natl. Acad. Sci. U. S. A. 102 2005 17308 17313
45. J. De Rijck Overexpression of the lens epithelium-derived growth factor/p75 integrase binding domain inhibits human immunodeficiency virus replication J. Virol. 80 2006 11498 11509
46. E. Serrao Discovery of a novel 5-carbonyl-1H-imidazole-4-carboxamide class of inhibitors of the HIV-1 integrase-LEDGF/p75 interaction Bioorg. Med. Chem. 21 2014 5963 5972
47. E. Le Rouzic Dual inhibition of HIV-1 replication by integrase-LEDGF allosteric inhibitors is predominant at the post-integration stage Retrovirology 10 2013 144
48. R. Dayam, and N. Neamati Small-molecule HIV-1 integrase inhibitors: the 2001-2002 update Curr. Pharm. Des. 9 2003 1789 1802
49. R. Dayam HIV-1 integrase inhibitors: 2005-2006 update Med. Res. Rev. 28 2008 118 154
50. K. Ramkumar HIV-1 integrase inhibitors: 2007-2008 update Med. Res. Rev. 30 2010 890 954
51. V. Summa Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection J. Med. Chem. 51 2008 5843 5855
52. E. Serrao Raltegravir, elvitegravir, and metoogravir: the birth of me-too HIV-1 integrase inhibitors Retrovirology 6 2009 25
53. S. Hare Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572) Mol. Pharmacol. 80 2011 565 572
54. T. Kohonen Self-organized formation of topologically correct feature maps Biol. Cybern. 43 1982 59 69
55. D.J. Hazuda Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells Science 287 2000 646 650
56. J.S. Wai 4-Aryl-2,4-dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells J. Med. Chem. 43 2000 4923 4926
57. A.S. Espeseth HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase Proc. Natl. Acad. Sci. U. S. A. 97 2000 11244 11249
58. G.C. Pais Structure activity of 3-aryl-1,3-diketo-containing compounds as HIV-1 integrase inhibitors 1 J. Med. Chem. 45 2002 3184 3194
59. X. Zhang Azido-containing aryl beta-diketo acid HIV-1 integrase inhibitors Bioorg. Med. Chem. Lett. 13 2003 1215 1219
60. M. Sechi Design and synthesis of novel indole β-diketo acid derivatives as HIV-1 integrase inhibitors J. Med. Chem. 47 2004 5298 5310
61. Y.Q. Long Rational design and synthesis of novel dimeric diketoacid-containing inhibitors of HIV-1 integrase: implication for binding to two metal ions on the active site of integrase J. Med. Chem. 47 2004 2561 2573
62. M.A. Walker Triketoacid inhibitors of HIV-integrase: a new chemotype useful for probing the integrase pharmacophore Bioorg. Med. Chem. Lett. 16 2006 2920 2924
63. Z. Wang Pharmacophore and structure-activity relationships of integrase inhibition within a dual inhibitor scaffold of HIV reverse transcriptase and integrase Bioorg. Med. Chem. Lett. 18 2010 4202 4211
64. M.L. Barreca Pharmacophore-based design of HIV-1 integrase strand-transfer inhibitors J. Med. Chem. 48 2005 7084 7088
65. L. Zhuang Design and synthesis of 8-hydroxy-[1,6] naphthyridines as novel inhibitors of HIV-1 integrase in vitro and in infected cells J. Med. Chem. 46 2003 453 456
66. M.W. Embrey A series of 5-(5,6)-dihydrouracil substituted 8-hydroxy-[1,6] naphthyridine-7-carboxylic acid 4-fluorobenzylamide inhibitors of HIV-1 integrase and viral replication in cells Bioorg. Med. Chem. Lett. 15 2005 4550 4554
67. J.P. Guare A series of 5-aminosubstituted 4-fluorobenzyl-8-hydroxy-[1,6] naphthyridine-7-carboxamide HIV-1 integrase inhibitors Bioorg. Med. Chem. Lett. 16 2006 2900 2904
68. B.A. Johns The use of oxadiazole and triazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 1: establishing the pharmacophore Bioorg. Med. Chem. Lett. 19 2009 1802 1806
69. B.A. Johns 1,3,4-Oxadiazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 2: SAR of the C5 position Bioorg. Med. Chem. Lett. 19 2009 1807 1810
70. S.E. Metobo Design, synthesis, and biological evaluation of novel tricyclic HIV-1 integrase inhibitors by modification of its pyridine ring Bioorg. Med. Chem. Lett. 16 2006 3985 3988
71. H. Jin Design, synthesis, and SAR studies of novel and highly active tri-cyclic HIV integrase inhibitors Bioorg. Med. Chem. Lett. 16 2006 3989 3992
72. M. Fardis Effect of substitution on novel tricyclic HIV-1 integrase inhibitors Bioorg. Med. Chem. Lett. 16 2006 4031 4035
73. S. Metobo Tricyclic HIV integrase inhibitors: VI. SAR studies of 'benzyl flipped' C3-substituted pyrroloquinolines Bioorg. Med. Chem. Lett. 19 2009 1187 1190
74. W.G. Verschueren Design and optimization of tricyclic phthalimide analogues as novel inhibitors of HIV-1 integrase J. Med. Chem. 48 2005 1930 1940
75. M. Sato Novel HIV-1 integrase inhibitors derived from quinolone antibiotics J. Med. Chem. 49 2006 1506 1508
76. S. Pasquini Investigations on the 4-quinolone-3-carboxylic acid motif. 1. Synthesis and structure-activity relationship of a class of human immunodeficiency virus type 1 integrase inhibitors J. Med. Chem. 51 2008 5125 5129
77. M. Sato Quinolone carboxylic acids as a novel monoketo acid class of human immunodeficiency virus type 1 integrase inhibitors J. Med. Chem. 52 2009 4869 4882
78. V. Summa 4,5-Dihydroxypyrimidine carboxamides and N-alkyl-5-hydroxypyrimidinone carboxamides are potent, selective HIV integrase inhibitors with good pharmacokinetic profiles in preclinical species J. Med. Chem. 49 2006 6646 6649
79. C. Gardelli Discovery and synthesis of HIV integrase inhibitors: development of potent and orally bioavailable N-methyl pyrimidones J. Med. Chem. 50 2007 4953 4975
80. M. Ferrara Development of 2-pyrrolidinyl-N-methyl pyrimidones as potent and orally bioavailable HIV integrase inhibitors Bioorg. Med. Chem. Lett. 20 2010 5031 5034
81. V. Nair HIV integrase inhibitors with nucleobase scaffolds: discovery of a highly potent anti-HIV agent J. Med. Chem. 49 2006 445 447
82. E. Muraglia Design and synthesis of bicyclic pyrimidinones as potent and orally bioavailable HIV-1 integrase inhibitors J. Med. Chem. 51 2008 861 874
83. E.D. Jones Design of a series of bicyclic HIV-1 integrase inhibitors. Part 1: selection of the scaffold Bioorg. Med. Chem. Lett. 20 2010 5913 5917
84. G. Le Design of a series of bicyclic HIV-1 integrase inhibitors. Part 2: azoles: effective metal chelators Bioorg. Med. Chem. Lett. 20 2010 5909 5912
85. N. Neamati Thiazolothiazepine inhibitors of HIV-1 integrase J. Med. Chem. 42 1999 3334 3341
86. K. Raghavan Three-dimensional quantitative structure-activity relationship (QSAR) of HIV integrase inhibitors: a comparative molecular field analysis (CoMFA) study J. Med. Chem. 38 1995 890 897
87. H. Zhao Arylamide inhibitors of HIV-1 integrase J. Med. Chem. 40 1997 1186 1194
88. K. Mekouar Styrylquinoline derivatives: a new class of potent HIV-1 integrase inhibitors that block HIV-1 replication in CEM cells J. Med. Chem. 41 1998 2846 2857
89. F. Zouhiri Structure-activity relationships and binding mode of styrylquinolines as potent inhibitors of HIV-1 integrase and replication of HIV-1 in cell culture J. Med. Chem. 43 2000 1533 1540
90. Z. Lin Chicoric acid analogues as HIV-1 integrase inhibitors J. Med. Chem. 42 1999 1401 1414
91. L. Yang Synthesis of polyhydroxylated aromatics having amidation of piperazine nitrogen as HIV-1 integrase inhibitor Bioorg. Med. Chem. Lett. 20 2010 5469 5471
92. D.C. Meadows Synthesis and biological evaluation of geminal disulfones as HIV-1 integrase inhibitors J. Med. Chem. 48 2005 4526 4534
93. D.C. Meadows Ring substituent effects on biological activity of vinyl sulfones as inhibitors of HIV-1 Bioorg. Med. Chem. 15 2007 1127 1137
94. M.C. Nicklaus HIV-1 integrase pharmacophore: discovery of inhibitors through three-dimensional database searching J. Med. Chem. 40 1997 920 929
95. C.L. Kuo Application of CoMFA and CoMSIA 3D-QSAR and docking studies in optimization of mercaptobenzenesulfonamides as HIV-1 integrase inhibitors J. Med. Chem. 47 2004 385 399
96. A. Mazumder Antiretroviral agents as inhibitors of both human immunodeficiency virus type 1 integrase and protease J. Med. Chem. 39 1996 2472 2481
97. H. Zhao Coumarin-based inhibitors of HIV integrase J. Med. Chem. 40 1997 242 249
98. H. Zhao Hydrazide-containing inhibitors of HIV-1 integrase J. Med. Chem. 40 1997 937 941
99. N. Neamati Salicylhydrazine-containing inhibitors of HIV-1 integrase: implication for a selective chelation in the integrase active site J. Med. Chem. 41 1998 3202 3209
100. J. Deng Dynamic receptor-based pharmacophore model development and its application in designing novel HIV-1 integrase inhibitors J. Med. Chem. 48 2005 1496 1505
101. J. Deng Dynamic pharmacophore model optimization: identification of novel HIV-1 integrase inhibitors J. Med. Chem. 49 2006 1684 1692
102. V. Hadi Development of the next generation of HIV-1 integrase inhibitors: pyrazolone as a novel inhibitor scaffold Bioorg. Med. Chem. Lett. 20 2010 6854 6857
103. S. Hare Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance Proc. Natl. Acad. Sci. U. S. A. 16 2010 20057 20062
104. N. Prada, and M. Markowitz Novel integrase inhibitors for HIV Expert Opin. Investig. Drug 19 2010 1087 1098
105. M. Kobayashi In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor Antimicrob. Agents Chemother. 55 2011 813 821
106. J.L. Blanco HIV-1 integrase inhibitor resistance and its clinical implications J. Infect. Dis. 203 2011 1204 1214
107. S.L. Ford Effects of etravirine on the pharmacokinetics of the integrase inhibitor S/GSK1265744 Antimicrob. Agents Chemother. 57 2013 277 280
108. S. Min Pharmacokinetics (PK) and safety in healthy and HIV-infected subjects and short-term antiviral efficacy of S/GSK1265744, a next generation once daily HIV integrase inhibitor The Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco 2009
109. W. Spreen Pharmacokinetics, safety and tolerability of the HIV integrase inhibitor S/GSK1265744 long acting parenteral nanosuspension following single dose administration to healthy adults XIX International AIDS Conference Washington, DC 2012